High sensitivity of chromogranin a (CgA) as serum marker of functioning and non-functioning digestive neuroendocrine tumors

2000 ◽  
Vol 118 (4) ◽  
pp. A647
Author(s):  
Carola Severi ◽  
Stefano Angeletti ◽  
Renato Cannizzaro ◽  
Vito D. Corleto ◽  
Paola Pradella ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Chromogranin A ◽  
High Sensitivity ◽  
Serum Marker

Chromogranin a Measurement in Neuroendocrine Tumors

1998 ◽  
Vol 13 (1) ◽  
pp. 3-9 ◽  
Author(s):  
L. Ferrari ◽  
E. Seregni ◽  
A. Martinetti ◽  
B Van Graafeiland ◽  
S. Nerini-Molteni ◽  
...  
Keyword(s):  
Tumor Marker ◽  
Neuroendocrine Tumors ◽  
Chromogranin A ◽  
High Sensitivity ◽  
Biologically Active ◽  
Proliferative Index ◽  
Favorable Prognosis ◽  
Blood Marker ◽  
Active Substances

Neuroendocrine tumors (NETs) are rare neoplasms characterized by a low proliferative index and, in some cases, a favorable prognosis. These tumors often overproduce and release biologically active substances that are responsible for severe syndromes. Tumor marker measurement provides the clinician with useful information for the management of NET patients. The substances released by overproducing tumors are currently used as biomarkers, but there is a need for sensitive markers also for the “biochemically silent” NETs. The most effective and reliable blood marker available today is chromogranin A (CgA). Because of its high sensitivity and specificity, this glycoprotein can be used for the diagnosis, prognosis and follow-up of NETs. Furthermore, CgA measurement can be used for monitoring those tumors not overproducing or releasing any hormones or biological amines. This paper is a synthetic review on the value of CgA in NET management and reports our experiences with CgA measurement in NET patients.

scholarly journals CLINICAL VALUE OF BIOCHEMICAL MARKERS OF NEUROENDOCRINE TUMORS

2019 ◽  
Vol 19 (1S) ◽  
pp. 28-29
Author(s):  
N V Lyubimova ◽  
Yu S Timofeev ◽  
M G Toms ◽  
T Yu Kharitidi ◽  
O I Vashketova ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Biochemical Markers ◽  
Chromogranin A ◽  
Endocrine System ◽  
Progression Free Survival ◽  
High Sensitivity ◽  
Biologically Active ◽  
Clinical Value ◽  
Diagnostic Significance

Neuroendocrine tumors (NET) is a heterogeneous group of epithelial neoplasms that develop from cells of the diffuse endocrine system and found in any organ. A distinctive feature of NET is the ability to produce various biologically active peptides and amines. Currently, the most useful markers are the universal marker chromogranin-A (CgA) and specific markers serotonin and 5-hydroxyindolylacetic acid (5-HIAA). The analysis of the clinical significance of the biochemical markers of NETs was carried out by comparative analysis of their levels in serum and urine of 339 NET patients and 66 healthy people. Determination of plasma CgA, serotonin in serum and 5-HIAA in daily urine was performed using standardized ELISA methods using the Chromogranin A ELISA kit (Dako), Serotonin ELISA and 5-HIAA ELISA (IBL) test-systems. The values of CgA, serotonin, 5-HIAA in patients with NET were significantly (p < 0.001) higher than the corresponding control values. Assessment of the diagnostic significance of CgA, taking into account the cut-off level 33 U/l (with a specificity of 98.5%), showed high sensitivity in the general NET group - 80.9%. The serial determination of the marker reflected the effect of treatment. The progression free survival in different treatment regimens for patients with NET has been associated with basal levels of CgA. The medians of serotonin and 5-HIAA levels were maximal in patients with carcinoid syndrome, significantly exceeding the corresponding values in NET patients without clinical manifestations.The data indicate the possibility of using CgA, serotonin and 5-HIAA to improve the accuracy of diagnosis, evaluation of generalization and biological activity of NETs.

scholarly journals Chromogranin A as Serum Marker for Gastroenteropancreatic Neuroendocrine Tumors: A Single Center Experience and Literature Review

Cancers ◽  
2012 ◽  
Vol 4 (1) ◽  
pp. 141-155 ◽  
Author(s):  
Svenja Nölting ◽  
Axel Kuttner ◽  
Michael Lauseker ◽  
Michael Vogeser ◽  
Alexander Haug ◽  
...  
Keyword(s):  
Literature Review ◽  
Neuroendocrine Tumors ◽  
Chromogranin A ◽  
Serum Marker ◽  
Single Center ◽  
Gastroenteropancreatic Neuroendocrine Tumors ◽  
Single Center Experience

Use of chromogranin a as specific serum marker in functioning and non-functioning digestive neuroendocrine tumors

2000 ◽  
Vol 32 ◽  
pp. A75
Author(s):  
C. Severi ◽  
S. Angeletti ◽  
R. Cannizzaro ◽  
V.D. Corleto ◽  
P. Pradella ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Chromogranin A ◽  
Serum Marker ◽  
Specific Serum

Pre-operative Diagnosis of Pancreatic Neuroendocrine Tumors with Endoscopic Ultrasonography and Computed Tomography in a Large Series

2016 ◽  
Vol 25 (3) ◽  
pp. 317-321 ◽  
Author(s):  
Raffaele Manta ◽  
Elisabetta Nardi ◽  
Nico Pagano ◽  
Claudio Ricci ◽  
Mariano Sica ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Neuroendocrine Tumors ◽  
Endoscopic Ultrasonography ◽  
Fine Needle Aspiration ◽  
Chromogranin A ◽  
Needle Aspiration ◽  
Large Series ◽  
Tumor Diameter ◽  
Pancreatic Neuroendocrine Tumors ◽  
Fine Needle

Background & Aims: Diagnosis of pancreatic neuroendocrine tumors (p-NETs) is frequently challenging. We describe a large series of patients with p-NETs in whom both pre-operative Computed Tomography (CT) and Endoscopic Ultrasonography (EUS) were performed. Methods: This was a retrospective analysis of prospectively collected sporadic p-NET cases. All patients underwent both standard multidetector CT study and EUS with fine-needle aspiration (FNA). The final histological diagnosis was achieved on a post-surgical specimen. Chromogranin A (CgA) levels were measured. Results: A total of 80 patients (mean age: 58 ± 14.2 years; males: 42) were enrolled. The diameter of functioning was significantly lower than that of non-functioning p-NETs (11.2 ± 8.5 mm vs 19.8 ± 12.2 mm; P = 0.0004). The CgA levels were more frequently elevated in non-functioning than functioning pNET patients (71.4% vs 46.9%; P = 0.049). Overall, the CT study detected the lesion in 51 (63.7%) cases, being negative in 26 (68.4%) patients with a tumor ≤10 mm, and in a further 3 (15%) cases with a tumor diameter ≤20 mm. CT overlooked the pancreatic lesion more frequently in patients with functioning than non-functioning p-NETs (46.5% vs 24.3%; P = 0.002). EUS allowed a more precise pre-operative tumor measurement, with an overall incorrect dimension in only 9 (11.2%) patients. Of note, the EUS-guided FNA suspected the neuroendocrine nature of tumor in all cases. Conclusions: Data of this large case series would suggest that the EUS should be included in the diagnostic work-up in all patients with a suspected p-NET, even when the CT study was negative for a primary lesion in the pancreas.– . Abbrevations: CgA: chromogranin A; EUS: Endoscopic Ultrasonography; FNA: fine-needle aspiration; p-NETs: pancreatic neuroendocrine tumors.

Quantification of chromogranin A with a surface plasmon resonance-based biosensor

2021 ◽  
Author(s):  
Yang Xiao ◽  
Yang Tai ◽  
Xin Quan ◽  
Chong Zhao ◽  
Rui Liu ◽  
...  
Keyword(s):  
Surface Plasmon Resonance ◽  
Surface Plasmon ◽  
Neuroendocrine Tumors ◽  
Plasmon Resonance ◽  
Chromogranin A ◽  
Traditional Methods

The chromogranin A (CgA) level in the blood is an important biomarker for neuroendocrine tumors and other diseases. Traditional methods for detecting CgA are expensive and time-consuming with low reproducibility....

Preoperative serum chromogranin-a is predictive of survival in locoregional jejuno-ileal small bowel neuroendocrine tumors

Surgery ◽  
2021 ◽  
Author(s):  
Praveen D. Chatani ◽  
John G. Aversa ◽  
James D. McDonald ◽  
Tahsin M. Khan ◽  
Xavier M. Keutgen ◽  
...  
Keyword(s):  
Small Bowel ◽  
Neuroendocrine Tumors ◽  
Chromogranin A ◽  
Preoperative Serum

Reply of the Authors: Comparing high-sensitivity C-reactive protein (hs-CRP) with CRP as a soluble serum marker for the diagnosis of women with endometriosis

2010 ◽  
Vol 94 (3) ◽  
pp. e52
Author(s):  
Johannes Lermann ◽  
Andreas Mueller ◽  
Frauke Körber ◽  
Peter Oppelt ◽  
Matthias W. Beckmann ◽  
...  
Keyword(s):  
High Sensitivity ◽  
Serum Marker ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Hs Crp
Sign in / Sign up

Export Citation Format

Share Document